Paris, France, April 4, 2024, 7:00 pm CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2024.


Information Date*
2024 1Q Cash Position April 4, 2024
Annual General Meeting May 29, 2024
2024 2Q Cash Position July 23, 2024
2024 First-Half Financial Update and Statements September 23, 2024
2024 3Q Cash Position October 24, 2024
2024 4Q Cash Position January 23, 2025

* This financial calendar is provided for information only and may be subject to changes. The Company’s updated financial calendar is available on its corporate website.